



HAL
open science

**Copper(II) and 24,25-(OH)₂D₃-copper(II) complex
inhibit circadian effects of 24,25-(OH)₂D₃ on
hypophysectomized rats APA sera activity.**

B. Do, G; Bouet, V. Annaix, Mustayeen A. Khan, P. Allain, X. Do Thanh

► **To cite this version:**

B. Do, G; Bouet, V. Annaix, Mustayeen A. Khan, P. Allain, et al.. Copper(II) and 24,25-(OH)₂D₃-copper(II) complex inhibit circadian effects of 24,25-(OH)₂D₃ on hypophysectomized rats APA sera activity.. Vitamin D. Chemistry, Bioogy and Clinical Applications of the Steroid Hormone., May 1997, Strasbourg, France. hal-03243897

HAL Id: hal-03243897

<https://univ-angers.hal.science/hal-03243897>

Submitted on 3 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

COPPER (II) AND 24,25-(OH)₂D₃-COPPER (II) COMPLEX INHIBIT CIRCADIAN EFFECTS OF 24,25-(OH)₂D₃ ON HYPOPHYSECTOMIZED RATS APA SERA ACTIVITY

B. DO¹, G. BOUET², V. ANNAIX³, M.A. KHAN², P. ALLAIN¹ and X. DÔ THANH¹
¹ Laboratoires de Pharmacologie/CHU² Chimie de Coordination, ³ Biochimie, Faculté de Pharmacie, 16 Boulevard Daviers, F- 49100 ANGERS- France.

Introduction

It has already been reported that the metabolism of Vitamin D₃ in hypophysectomized (Hx) rats is disturbed : sera 1 α ,25(OH)₂D₃ decreases while 24,25(OH)₂D₃ production is slightly increased (1). Alkaline phosphatase (APA) activity is depressed (2). DO *et al.* (3, 4) have demonstrated that intraperitoneal (ip) injections of 24,25(OH)₂D₃ induce an increase in APA and γ -glutamyl-transferase (GGT) activities in rats brain and kidneys. It interesting to investigate whether these enzymatic activities could also be modified in sera of Hx rats.

Materials and Methods

Intact and Hx male Sprague-Dawley rats from Iffa-Credo (France) weighing, on receiving day, from 180-220 g were used. Five series of 4 rats were used and each animal received a single intraperitoneal (ip) injection (50 μ l) at 03.00 h. Treatments were as follow:

- control series: animals received vehicle (aqueous NaCl 9 g.l⁻¹)
- series 1 : copper (II) chloride (4.8.10⁻⁷ mol.l⁻¹)
- series 2 : 24,25(OH)₂D₃ (4.8 10⁻⁷ mol.l⁻¹)
- series 3 : [CuCl₂(24,25 (OH)₂ D₃)] complex (4.8 10⁻⁷ mol.l⁻¹)
- intact series: intact animals received vehicle (aqueous NaCl 9g l⁻¹)

At night time all animals were killed 3 h after ip, when enzymatic activities were at their highest levels (5). The same protocol was used at day time (ip at 15.00 h). APA (Enzyline kit[®], Biomerieux) and GGT (GGT kit[®], Boehringer) activities were tested in sera.

Results and Discussion

In intact and in Hx rats values of sera APA activity were lower during day time than night time (Tables I & II). Hypophysectomy depresses APA values when compared to intact rats (- 43 % p < 0.05). Sera GGT activity could not be detected (6). During day, 3 h after injection 24,25(OH)₂D₃ inhibits APA activity in Hx rats (- 26% p < 0.05). At night time 24,25(OH)₂D₃ is more potent on sera APA activity as compared to day time (- 48 % vs -26 % p < 0.05).

These results are consistent with previous study demonstrating that 24,25(OH)₂ D₃ inhibits directly parathyroid hormone (PTH) action on bone through abolishment of PTH-stimulated adenylate cyclase activity (7). Copper (II) and the complex suppress secosteroid effects, it's more effective at night time than during day time. These data prove that rats are more sensitive to the effects of 24,25(OH)₂D₃ on sera APA activity during night than during day. Copper (II) and

the complex abolish secosteroid effects and this can be explained on the basis of circadian chronopharmacology.

Table I - Day time effects of 24,25(OH)₂D₃, copper(II) and 24,25(OH)₂D₃-copper(II) complex on sera (APA) activity (mU/ml, means \pm s.d.) in Hx rats 3 h after i.p. injection (15.00 h) and sacrifice (18.00h), Mann-Whitney test with p < 0.05.

Intact rats a	Hypophysectomized rats			
	Controls b	24,25(OH) ₂ D ₃ ^c	Copper(II) ^d	Complex ^e
207 \pm 28	145 \pm 23, a \neq b -30 % p<0.05	107 \pm 10, b \neq c -26 % p<0.05	133 \pm 25, b \neq d - 8 % n.s.	147 \pm 39, b \neq e n.s.

Table II - Night time effects of 24,25(OH)₂D₃, copper(II) and 24,25(OH)₂D₃-copper(II) complex on sera (APA) activity.

Intact rats aa	Hypophysectomized rats			
	Controls bb	24,25(OH) ₂ D ₃ ^{cc}	Copper(II) ^{dd}	Complex ^{ee}
728 \pm 84	387 \pm 126, aa \neq bb -47 % p<0.05	107 \pm 10 bb \neq cc -48 % p<0.05	133 \pm 25 bb \neq dd - 5 % n.s.	147 \pm 39 bb \neq ee n.s.
	aa \neq bb, 72% p<0.05			

a \neq aa : + 71 %, p<0.05 b \neq bb : + 62 %, p>0.05 c \neq cc : +47 %, p<0.05

References

- 1 - Wongsurawat N., Armbrecht H.J., Zenser T.Y., Forte L.R., Davis B.B. (1984) *J. Endocr.* **101**, 333-338.
- 2 - Prelot M., Do T.X., Planchenault P., Girault A. (1990) *Arch. Int. Physiol. Biochim.* **98**, 59-66.
- 3 - Darcy F., Sindji L., Peter J.C., Garcion E., Girault A., Khan M.A., Brachet P., Do T.X. (1994). In *Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications* pp.640-641. W. de Gruyter, Berlin- New York.
- 4 - Do T.X., Peter J.C., Girault A., Rabjeau A., Bouet G., Sindji L., Darcy F. (1994) In *Vitamin D. Ibid.* pp .745-746.
- 5 - Do T.X., Boissnard P., Girault A., Planchenault P., Breget R., Prelot M.(1992) *Sci. Tech. Anim. Lab.* **17**, 207-211.
- 6 - Laroche M.J., Rousselet F.(1990) In *Les animaux de laboratoire. Ethique et bonnes pratiques* pp.1-393. Masson. Paris.
- 7 - Mortensen B., Aarseth H.P., Haug E., Gautvik K.M., Gordeladze J.O.(1991) In *Vitamin D. Gene Regulation. Structure-Function Analysis and Clinical Application* pp.863-864. W. de Gruyter, Berlin-New York.

Acknowledgements

24,25(OH)₂D₃ is a gift from Dr Nobuyuki Taniguchi, Kureha Chemical Ltd, Tokyo, Japan.